Biomaterial-mediated intracellular control of macrophages for cell therapy in pro-inflammatory and pro-fibrotic conditions

• Published in: Biomaterials 2024-07, Vol.308, p.122545-122545, Article 122545
• Main Authors: Tylek, Tina, Wong, Joanna, Vaughan, Andrew E., Spiller, Kara L.
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Biocompatible Materials - chemistry; Cell therapy; Cell- and Tissue-Based Therapy - methods; Dexamethasone - pharmacology; Dexamethasone - therapeutic use; Fibrosis; Immunomodulation; Inflammation - pathology; Lactic Acid - chemistry; Macrophage polarization; Macrophages - drug effects; Macrophages - metabolism; Mice; Mice, Inbred C57BL; Phagocytosis - drug effects; Polyglycolic Acid - chemistry; Polylactic Acid-Polyglycolic Acid Copolymer - chemistry; Pulmonary fibrosis; Pulmonary Fibrosis - pathology; Pulmonary Fibrosis - therapy; RAW 264.7 Cells
• ISSN: 0142-9612; 1878-5905; 1878-5905
• DOI: 10.1016/j.biomaterials.2024.122545

Macrophages are key modulators of all inflammatory diseases and essential for their resolution, making macrophage cell therapy a promising strategy for regenerative medicine. However, since macrophages change rapidly in response to microenvironmental cues, their phenotype must be controlled post-administration. We present a tunable biomaterial-based strategy to control macrophages intracellularly via small molecule-releasing microparticles. Poly(lactic-co-glycolic acid) microparticles encapsulating the anti-inflammatory and anti-fibrotic drug dexamethasone were administered to macrophages in vitro, with uptake rates controlled by different loading regimes. Microparticle dose and dexamethasone content directly affected macrophage phenotype and phagocytic capacity, independent of particle content per cell, leading to an overall pro-reparative, anti-inflammatory, anti-fibrotic phenotype with increased phagocytic and ECM degrading functionality. Intracellularly controlled macrophages partially maintained this phenotype in vivo in a murine pulmonary fibrosis model, with more prominent effects in a pro-fibrotic environment compared to pro-inflammatory. These results suggest that intracellular control using biomaterials has the potential to control macrophage phenotype post-administration, which is essential for successful macrophage cell therapy.